Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Am J Cardiol. 2011 Dec 1;108(11):1606-13. doi: 10.1016/j.amjcard.2011.07.019. Epub 2011 Sep 21.
In hypertrophic cardiomyopathy (HC), electrocardiographic (ECG) changes have been postulated to be an early marker of disease, detectable in sarcomere mutation carriers when left ventricular (LV) wall thickness is still normal. However, the ECG features of mutation carriers have not been fully characterized. Therefore, we systematically analyzed ECGs in a genotyped HC population to characterize ECG findings in mutation carriers (G+) with and without echocardiographic LV hypertrophy (LVH), and to evaluate the accuracy of ECG findings to differentiate at-risk mutation carriers from genetically unaffected relatives during family screening. The ECG and echocardiographic findings were analyzed from 213 genotyped subjects (76 G+/LVH-, 57 G+/LVH+ overt HC, 80 genetically unaffected controls). Cardiac magnetic resonance imaging was available on a subset. Q waves and repolarization abnormalities (QST) were highly specific (98% specificity) markers for LVH- mutation carriers, present in 25% of G+/LVH- subjects, and 3% of controls (p <0.001). QST ECG abnormalities remained independently predictive of carrying a sarcomere mutation after adjusting for age and impaired relaxation, another distinguishing feature of G+/LVH- subjects (odds ratio 8.4, p = 0.007). Myocardial scar or perfusion abnormalities were not detected on cardiac magnetic resonance imaging in G+/LVH- subjects, irrespective of the ECG features. In overt HC, 75% had Q waves and/or repolarization changes, but <25% demonstrated common isolated voltage criteria for LVH. In conclusion, Q waves and repolarization abnormalities are the most discriminating ECG features of sarcomere mutation carriers with and without LVH. However, owing to the limited sensitivity of ECG and echocardiographic screening, genetic testing is required to definitively identify at-risk family members.
在肥厚型心肌病 (HC) 中,心电图 (ECG) 变化被认为是疾病的早期标志物,在左心室 (LV) 壁厚度仍正常时,可在肌节突变携带者中检测到。然而,突变携带者的 ECG 特征尚未完全确定。因此,我们系统地分析了经基因分型的 HC 人群中的 ECG,以描述无超声心动图 LV 肥厚 (LVH) 和有 LVH 的突变携带者 (G+) 的 ECG 特征,并评估 ECG 特征在家族筛查中区分高危突变携带者和遗传上无影响的亲属的准确性。分析了 213 名经基因分型的受试者 (76 名 G+/LVH-,57 名 G+/LVH+显性 HC,80 名遗传上无影响的对照) 的 ECG 和超声心动图结果。部分受试者进行了心脏磁共振成像检查。Q 波和复极异常 (QST) 是 LVH-突变携带者的高度特异性 (特异性 98%) 标志物,25%的 G+/LVH-受试者和 3%的对照组存在该标志物 (p<0.001)。在调整年龄和舒张功能障碍后,QST ECG 异常仍然是携带肌节突变的独立预测因素,这是 G+/LVH-受试者的另一个区别特征 (优势比 8.4,p=0.007)。在 G+/LVH-受试者中,无论 ECG 特征如何,心脏磁共振成像均未检测到心肌瘢痕或灌注异常。在显性 HC 中,75%有 Q 波和/或复极变化,但<25%符合 LVH 的常见孤立电压标准。总之,Q 波和复极异常是伴或不伴 LVH 的肌节突变携带者最具鉴别力的 ECG 特征。然而,由于 ECG 和超声心动图筛查的敏感性有限,需要进行基因检测以明确识别高危家庭成员。